Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | BCL3 | P20749 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13385672 | 0.90 | POLB (0.61) | KMT2AMEN1BCL3HPGDALDH1A1 | |
| SCHEMBL2964718 | 0.86 | IKBKB (0.57) | KMT2AMEN1ALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL7527740 | 0.85 | KMT2A (0.66) | KMT2AMEN1BCL3HPGDCD274 | |
| SCHEMBL8167729 | 0.85 | KMT2A (0.66) | KMT2AMEN1BCL3HPGDCD274 | |
| SCHEMBL13164059 | 0.85 | MEN1 (0.66) | KMT2AMEN1BCL3HPGDCD274 | |
| SCHEMBL8161181 | 0.85 | BCL3 (0.84) | KMT2AMEN1BCL3HPGDCD274 | |
| SCHEMBL21347706 | 0.85 | KMT2A (0.66) | KMT2AMEN1BCL3HPGDCD274 | |
| SCHEMBL2413238 | 0.84 | MEN1 (0.50) | KMT2AMEN1BCL3ALDH1A1 | |
| SCHEMBL8356152 | 0.84 | CYP1A2 (0.68) | KMT2AMEN1HPGDCD274ALDH1A1 | |
| SCHEMBL10352662 | 0.84 | KMT2A (0.65) | KMT2AMEN1BCL3HPGDCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | KMT2A 598/4885MEN1 1646/4885BCL3 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.